In line with this, the burden of TAI and LOH could successfully predict (AUC = 0.74) the response of breast cancer patients to cisplatin in two phase 2 clinical trials (NCT00148694 and NCT00580333), an association that remained significant when only wild-type BRCA1/2 cases were included [30,34]. Here, BRCA1 is linked to breast carcinoma.